Vol 22 No 1 (2016)
Journal of Commercial Biotechnology
Journal of Commercial Biotechnology
Subscribe
Current
Archives
Search
About
About the Journal
Submissions
Editorial Team
Privacy Statement
Contact
Register
Login
Register
Login
Vol 22 No 1 (2016)
Published May 5, 2016
Commentary
Anthony Johnson
An Impediment to Personalized Medicine Commercialization is the Lack of Understanding of the Value of the Testing
Requires Subscription or Fee
PDF
Articles
Julia Schueler, Tobias Ostler
Biopharmaceutical Startup’s Need of a Regulatory Strategy
Requires Subscription or Fee
PDF
Weifan Zhang, Rebecca Liu, Chris Chatwin
Marketing authorization of medical devices in China
Requires Subscription or Fee
PDF
Demetris Iacovides
VC-backed Biotechnology Firms: What is Entrepreneurs’ Return?
Requires Subscription or Fee
PDF
Elizabeth Ann McCaman
Encouraging Innovation in Preventive Health Technology: A Spotlight on Women's Health
Requires Subscription or Fee
PDF
Kristina M Lybecker
Intellectual Property Protection for Biologics: Why the Trans-Pacific Partnership (TPP) Trade Agreement Fails to Deliver
Requires Subscription or Fee
PDF
Thani Jambulingam, Carolin Schellhorn, Rajneesh Sharma
Using a Rasch Model to Rank Big Pharmaceutical Firms by Financial Performance
Requires Subscription or Fee
PDF
Conference Report
Vasu Pestonjamasp
Moving from preclinical research to development
Requires Subscription or Fee
PDF
×
Username
*
Required
Password
*
Required
Forgot your password?
Keep me logged in
Login
No account?
Register here